Niagen Bioscience, Inc. current report, 09 August 2018

SEC Filing Summary: ChromaDex Corporation (8-K)

Business Context and Reporting Period

This Form 8-K was filed by ChromaDex Corporation on August 9, 2018. The filing serves to announce the Company's earnings results for the quarter ended June 30, 2018, and to disclose a corporate presentation made available on the Company's website. The registrant is incorporated in Delaware and is headquartered in Irvine, California.

Key Financial Metrics

The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are not included in the source text.

Material Changes

The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of the Q2 2018 earnings announcement and the accompanying corporate presentation.

Guidance, Outlook, and Risks

Management commentary, guidance, and outlook are referenced as being included in the attached corporate presentation (Exhibit 99.2). The filing explicitly states that the information in Items 2.02 and 7.01 is furnished and not "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.

Investor Verification Checklist

  • Review the attached Press Release (Exhibit 99.1) for specific Q2 2018 revenue and net income figures.
  • Examine the Investor Presentation (Exhibit 99.2) for forward-looking guidance and strategic updates.
  • Verify the Company's cash position and debt levels in the full quarterly report (10-Q) referenced by this 8-K.
  • Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.